anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a preparation method of a multi-functional polysaccharide compound and the medicinal use of the multi-functional polysaccharide compound, and relates to a corn peel polysaccharide compound extracted through the biological enzymolysis method. The corn peel polysaccharide compound comprises polysaccharides, polypeptides and polyphenol components, and has the functions of oxidation resistance and aging resistance. The molecular weight of the corn peel polysaccharide compound is 500 Da-21 kDa, and the average molecular weight of the corn peel polysaccharide compound is 17.9 kDa. The corn peel polysaccharide compound has the functions of resisting oxidation, reducing blood fat and delaying senescence. The corn peel polysaccharide compound can be used for preparing anti-oxidation and anti-aging drugs in the fields of health-care foodstuffs, cosmetics and the like. The additional value of grain crops is improved. Meanwhile, the preparation process has the advantages of no pollution and zero emission.
The object is to provide a peptide having higher affinity to hemagglutinin, a peptide having a high inhibitory activity on the infection with an influenza virus, and a pharmaceutical composition comprising any one of the peptides. Peptides having a mutation in the sequence: ARLSPTMVHPNGAQP (peptide A-1; SEQ ID NO:1) are prepared, and screening is made for a peptide having higher affinity to hemagglutinin. As a result, polypeptides comprising the sequences depicted in SEQ ID NOs:2-7, 9-10 and 12-18 can be obtained. These peptides can be used as the peptide mentioned above. In a peptide having the sequence depicted in SEQ ID NO:3, when the C-terminus of the sequence of SEQ ID NO:3 is removed so as to allowing ARLPR or ARLP to remain, the inhibitory activity of the peptide on the infection with an influenza virus can be increased. An inhibitor of the infection with an influenza virus or a prophylactic/therapeutic agent for influenza can be prepared by formulating the above-mentioned influenza virus receptor-binding peptide.
PURPOSE:To obtain an incense stick improved in a clear and bright visual color without reducing the volatilization ratio of the active components or its effect. CONSTITUTION:This incense stick is composed of a combustion base, a sizing agent, active components, a pigment, aluminum hydroxide and others. The content of aluminum hydroxide is >=2.5wt.%. A specifical example is an incense stick prepared from 13.0wt.% wood powder, 33.8wt.% pyrethrum-extraction lees, 13.0wt.% tea powder, 20.0wt.% powder of wheat-gluten bread, 20.0wt.% aluminum hydroxide and 0.2wt.% malachite green by a known kneading method. This exemplified incense stick has a visual color of 2.5G hue, brightness of 5 and chroma of 6 (respectively based on standard color JISZ8721). It is improved in clearness and brightness in comparison with brightness of 3 and chroma of 4 in the case in which aluminum hydroxide is not contained.
Haemorrhage from junctional injuries remains the most common cause of battlefield death. Changes to surgical training have meant acquiring and maintaining trauma surgical skills is becoming more difficult for military surgeons. The multidisciplinary Military Operational Specialist Team Training (MOSTT) course is designed to bridge the gap between civilian practice and the deployed environment, as part of predeployment trauma training. It involves immersive team simulation and uses cadaveric dissection for surgical skills practice.A novel surgical anatomy model, featuring junctional haemorrhage surgical task trainers of the groin and shoulder, was designed using reconstructed CT and MRI images obtained from a human volunteer. The model is designed to look and feel as realistic as possible, with the added dimension of pulsatile 'blood' flow from a simulation gunshot injury.This surgical anatomy model has been trialled, as part of the MOSTT course, by 90 surgeons and perioperative practitioners, with feedback analysis used for iterative model development. Feedback demonstrated that, alongside more traditional cadaveric dissection, this surgical anatomy model adds value to current predeployment training delivered within the immersive simulation of the MOSTT course. Research by the authors about the effects of this model on surgical ability and performance is ongoing. However, there is clear potential for this model to be used in other environments, including on exercises and as part of consolidation training while deployed.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and can be used for treating secondary neovascular glaucoma. That is ensured by the intravenous drop-by-drop introduction of a chlorine photosensitiser (PS) for 10 minutes in dosage 0.8 mg/kg of body weight. 10 minutes after the PS introduction, retina is exposed to transpupillary laser radiation at power density 40-50 J/cm2. The exposure is concentric from the arcades up to an extreme periphery in fields 4 mm in diametre overlapping of the adjacent fields by 5% of the area. ^ EFFECT: method allows higher early-stage clinical effectiveness in secondary neovascular glaucoma, prevented development of neovascularisation of the anterior eye segment with a complete organic block of an angle of anterior chamber and following decompensation of intraocular pressure due to photoinduced retinal and choroid thrombosis within an exposure coverage, and formation of chorioretinal atrophy centres, and thereby arrested development of angiogenic factors.
Administer one tablet under the tongue or in the buccal pouch at the first sign of an acute anginal attack. Allow tablet to dissolve without swallowing. One additional tablet may be administered every 5 minutes until relief is obtained. No more than three tablets are recommended within a 15-minute period. If the pain persists after a total of 3 tablets in a 15-minute period, or if the pain is different than is typically experienced, seek prompt medical attention.

Nitroglycerin sublingual tablets may be used prophylactically 5 to 10 minutes prior to engaging in activities that might precipitate an acute attack.

For patients with xerostomia, a small sip of water prior to placing the tablet under the tongue may help maintain mucosal hydration and aid dissolution of the tablet. 

Administer nitroglycerin sublingual tablets at rest, preferably in the sitting position.
The method of early diagnosis of the depth of burn lesions comprises the thermography of the burn surface and the surrounding tissues followed by application of the cloth soaked ozonized saline and repeated thermography. The depth of burn lesion is assessed based on the comparison of the changes in surface temperatures. At the same time, the intravenous dropwise infusion of ozonized saline is provided. For application, the cold (3-5 °C) solution of the ozonized lipin and Dioxysol-Darnytsia at a 5:1 ratio is used, the exposure time is 3-4 min. When the cloth is removed, the intermediate control thermography is provided over the whole surface. The depth of burn lesion is assessed based on the comparison of the changes in surface temperatures measured in the second vs. third thermography. The increase in the skin temperature difference by more than 1.0±0.2 °C is indicative of the surface lesion with spared peripheral blood flow in the adjacent area of paranecrosis. The increase in the skin temperature difference by less than 1.0±0.2 °C is indicative of deep dermal lesion with paranecrotic area and the progression of the burn lesion in the adjacent tissues.
In addition to the health literature, participants completed the Facial Morphing Intervention. Participants had a digital photograph taken and uploaded to the APRIL® software, accompanied by information about their current age and self-identified race. Participants were presented with two, side-by-side identical 2D images of their face. Participants first viewed an image of their face from their current age, in two-year intervals, to age 72, the maximum age, with the "UV exposure" setting turned on. This process was repeated. Next, participants viewed the projected aging process, toggling the "UV exposure" setting (on and off), every ten year interval. The process was repeated using 3D images to view projected changes to their facial profiles.
It has been developed a new active principle of salt S(-)-5-benzonyl-2, 3-dihydro-1H-pyrrolizine-1-carboxyc acid 2-amino-2-(hydroxymethyl)-1,3-propanediol or generically known as S- Ketorolac tromethamine. This salt is constituted by the S enantiomer, which is the most active, this being 75 folds more active than the R form, which enables the dose to be reduced down to 50%, therefore reducing severe side effects presented by the chronic consumption of the drugs based on the current racemic salt of Ketorolac. In addition, the active principle of the present invention offers improvements in physic-chemical properties such as a higher speed of intrinsic dissolution and an improved solubility in polar media, compared to the racemic salt of Ketorolac tromethamine. These properties provide a higher efficiency upon being absorbed in a quicker manner and in a higher amount. This provides a quicker analgesic response for actuating against severe pain in a more immediate manner with an increase d analgesic potency, this property being desired in severe traumatisms or wounds and further ailments of terminal type, such as cancer or neuropathies in general and diabetic neuropathy in particular. The combinations with other compounds useful in different analgesia and neuropathies allow more efficient drugs to be developed with different synergic effects that provide the patient, especially those who use them in a chronic manner, a better quality of life.
The results of patients who underwent surgery for acute cholecystitis in a single center between January 2016 and December 2019 were included and evaluated retrospectively.

Primary outcome was subtotal cholecystectomy rate. Secondary outcomes were conversion to open, complications and serious complications. Within examining demographic findings, operative records (rates for subtotal cholecystectomy and conversion to open, operative duration) and follow-up results (postoperative complications, serious complications, length of hospital stay and mortality) for all cases were investigated. Complications that Clavien-Dindo Score ≥ 3 accepted as serious complication. Intraoperative detection of gallbladder perforation was also noted and included in comparison. Any biliary tract complication that needed any percutaneous or endoscopic intervention to handle was named as "biliary leak" in the study.
Eligible patients will receive lapatinib (1250 mg given orally once daily on days 1 through 21) in combination with capecitabine (2000 mg/m2/day administered orally in 2 doses approximately 12 hours apart on days 1 through 14). Treatment will be organized into cycles of 21 days .
Lifetime carcinogenicity studies were carried out in CD-1 mice and Long-Evans rats at doses up to 40 mg/kg/day. These doses correspond to 1 times (mice) and 2 times (rats) the maximum recommended human dose (MRHD) on a mg/m2 basis. There was a dose-related increase of liver adenomas in male mice receiving sertraline at 10 to 40 mg/kg (0.25 to 1 times the MRHD on a mg/m2 basis). No increase was seen in female mice or in rats of either sex receiving the same treatments, nor was there an increase in hepatocellular carcinomas. Liver adenomas have a variable rate of spontaneous occurrence in the CD-1 mouse and are of unknown significance to humans. There was an increase in follicular adenomas of the thyroid in female rats receiving sertraline at 40 mg/kg (2 times the MRHD on a mg/m2 basis); this was not accompanied by thyroid hyperplasia. While there was an increase in uterine adenocarcinomas in rats receiving sertraline at 10 to 40 mg/kg (0.5 to 2 times the MRHD on a mg/m2 basis) compared to placebo controls, this effect was not clearly drug related.
Initial evaluations will be made for all participants. Then, they will continue their routine basketball training programs for 3 weeks.
For tibialis anterior muscle taping, each children's feet were placed at plantar flexion and eversion position while knees were extended, and I-shaped band was applied over tibialis anterior from origin to insertion of muscle with approximately 25-50% tension of the original length of the band. No tension was applied to the first and last 5 cm section of the bands in both applications because it were used as anchor. The tapes were remained for 1 hour on skin of both quadriceps and tibialis anterior muscles, and in this time the children were rested.
Schizophrenia is one of the most important diseases that threaten the health of Chinese people. In view of the current lack of objective biological markers in the diagnosis and treatment of schizophrenia, as well as the lack of effective early diagnosis methods and curative effect prediction methods, the investigators carried out joint research by integrating research teams from molecular genetics, neurobiochemistry, psychiatry, medical imaging, information science and other fields. The overall objective of the project is to establish a bio-marker system for individualized diagnosis and treatment of early schizophrenia. Specific research contents include: screening and verifying multidimensional objective biological markers such as genetics, neurobiochemistry, neuroimaging, electrophysiology, which is related to early diagnosis and efficacy prediction of schizophrenia through big data analysis of healthy controls and patients with first episode schizophrenia, depression and anxiety disorder. Pattern recognition method is used to build the individualized early diagnosis model, biological sub-type clustering model, biological sub-type individualized diagnosis model and early curative effect prediction model of schizophrenia. Based on the individualized diagnosis and treatment prediction model of schizophrenia, the individualized diagnosis and treatment toolkit was developed, and the individualized diagnosis and treatment prediction cloud platform was established to provide assist for clinicians.
Subjects assigned to this group will be instructed on how to wear the device to produce the appropriate amount of dorsiflexion (stretch). Splint devices will be worn at the assigned angle 5 days/week, 30 minutes/day, for 4 weeks. ABI, muscle oxygenation, and walking distance will be assessed pre/post stretching. Other health surveys will be administered.
PCT No. PCT/NL96/00244 Sec. 371 Date Mar. 25, 1997 Sec. 102(e) Date Mar. 25, 1997 PCT Filed Jun. 14, 1996 PCT Pub. No. WO97/00326 PCT Pub. Date Jan. 3, 1997Presented are ways to address the problem of replication competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector and are suited for large scale production of recombinant adenoviruses. A system for use with the invention produces adenovirus incapable of replicating. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, and further has at least one functional encapsidating signal, and at least one functional Inverted Terminal Repeat. The isolated recombinant nucleic acid molecule lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.
This is a multi-center, multi-reader, open-label trial, comparing 99mTc-MIP-1404 SPECT/CT imaging in men who have had a diagnostic trans-rectal ultrasound (TRUS) guided biopsy with a histopathologic finding of Gleason score ≤3+4 who are candidates for active surveillance and are undergoing routine biopsy or voluntary RP with or without a pelvic lymph node dissection (PLND). This study will evaluate the sensitivity and specificity of 99mTc-MIP-1404 SPECT/CT image assessments to correctly identify subjects with previously unknown clinically significant prostate cancer in two cohorts: (1) Low grade prostate cancer who have elected to undergo RP \[Cohort A\]; and (2) very low risk (VLR) prostate cancer per 2016 NCCN Guidelines who are scheduled to undergo routine prostate biopsy \[Cohort B\].

Subjects will receive a single dose of 99mTc-MIP-1404 Injection (study drug) followed by whole body planar and SPECT/CT (pelvic) imaging 3-6 hours after injection. In accordance with standard of care procedures, subjects will undergo either voluntary RP \[Cohort A\] or prostate biopsy \[Cohort B\] within 42 days after study drug dosing. 99mTc-MIP-1404 image data will be collected by a central imaging core laboratory and evaluated for visible uptake within the prostate gland. These findings will then be compared against central histopathology as the truth standard. The central imaging core lab independent readers for the SPECT/CT scans will be blinded to all clinical data, including pathology results. Likewise, central pathologists are to remain blinded to all clinical data, including imaging results.
The most frequent adverse reactions to tobramycin ophthalmic solution 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with tobramycin ophthalmic solution.

To report SUSPECTED ADVERSE REACTIONS, contact Belcher Pharmaceuticals, LLC at 1-727-471-0850 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Postmarketing Experience: Additional adverse reactions identified from post-marketing use include anaphylactic reaction, Stevens-Johnson syndrome, and erythema multiforme.

The following additional adverse reactions have been reported with systemic aminoglycosides: Neurotoxicity, ototoxicity and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.
FIELD: medicine, pharmaceutical industry. SUBSTANCE: method involves preparing polysaccharide and biologically active substance solutions, successive components mixing, sublimation drying of mixture. Alginic acid and its salts, mixture of alginates with chitosan, carraghinan were used as polysaccharides. Hyaluronidase, proteolytical complex, cytochrome c and deoxyribonucleic acid (DNA) or their biochemically compatible salts were used as biologically active substances. One gram of the end product must contain 5-25 mg cytochrome c, 15-50 conventional units of proteolytical activity, 30-60 units of hyaluronidase activity and 80-120 mg DNA or their mixtures taken at amount corresponding low value of indicated concentration range. EFFECT: improved method of preparing. 4 cl
The zonal acupuncture group will receive a treatment according to a zonal method and a pain level will be estimated by the investigator according to a visual analog pain scale (VAS) before and 10 minutes and 15 minutes after the beginning of the treatment and the change of the pain level will be recorded. If possible the pain level will be measured again approximately 24 hours after the treatment and the change of the pain level will be again recorded.
Prepn. of an attenuated syncytial respiratory vaccine comprises senal passage of a virus in human diploid pulmonary fibroblasts at 30-38oC for a sufficient number of passages to attenuate its power, then recovering the virus A vaccine esp. contains frozen attenuated virus and a stabilizer, esp.  Sorbitol and gelatin.  This vaccine is used for prevention of respiratory disorders, esp. in children.  A typical vaccine was prepd. from a virus isolated from the throat subjected to two passages in monkey kidney cells then four passages in human diploid pulmonary fibroblast (WI-38).  The collected infected cell was grown in modified Eagle's medium.
Radial glial cells (RGCs) are remarkable cells, essential for normal development of the vertebrate central nervous system. In teleost fishes, RGCs play a pivotal role in neurogenesis and regeneration of injured neurons and glia. RGCs also exhibit resilience to environmental stressors like hypoxia via metabolic adaptations. In this study, we assessed the physiology of RGCs following varying degrees of hypoxia, with an emphasis on reactive oxygen species (ROS) generation, mitochondrial membrane potential (MMP), mitophagy, and energy metabolism. Our findings demonstrated that hypoxia significantly elevated ROS production and induced MMP depolarization in RGCs. The mitochondrial disturbances were closely associated with increased mitophagy, based on the co-localization of mitochondria and lysosomes. Key mitophagy-related genes were also up-regulated, including those of the BNIP3/NIX mediated pathway as well as the FUNDC1 mediated pathway. Such responses suggest robust cellular mechanisms are initiated to counteract mitochondrial damage due to increasing hypoxia. A significant metabolic shift from oxidative phosphorylation to glycolysis was also observed in RGCs, which may underlie an adaptive response to sustain cellular function and viability following a reduction in oxygen availability. Furthermore, hypoxia inhibited the synthesis of mitochondrial complexes subunits in RGCs, potentially related to elevated HIF-2α expression with 3 % O2. Taken together, RGCs appear to exhibit complex adaptive responses to hypoxic stress, characterized by metabolic reprogramming and the activation of mitophagy pathways to mitigate mitochondrial dysfunction.
Participants in this group will receive PAP therapy which is the standard of care. Participants will be in this group for approximately 3 months.
The IBDMicro is an interventional, randomized, double-blind, placebo-controlled study. A novel oral formulation of butyrate contained in a lipophilic microcapsule, that provides extensive capacity for intestinal diffusion and facilitates slow release of the active ingredient will be used ("Butyrose" produced by SILA SRL, Italy). A proof-of-concept study has been already published in this context, and preliminary data showed that butyrate administration was able to change the gut microbiota of patients with IBD and IBS-D after 12 weeks of treatment, in association with the changes of intestinal inflammation indexes (fecal calprotectin). In keeping, investigators will assess the microbiota before and after the butyrate administration. Also, clinical data will be collected by using validated disease-specific questionnaires (Rome IV and clinical indexes for IBD). Quality of life will be also recorded. The analysis of intestinal microbiota will be carried out by collecting a fecal sample and analyzed with metagenomics techniques.
Medication administration methods are provided for treating cardiovascular disease. A method may include administering a baseline dosage of the medication to a patient. A flow diverting apparatus may be implanted into a vessel of the patient such that blood pressure to the patient's kidneys is increased. The flow diverting apparatus is structured to partially occlude blood flow through the vessel when implanted thereby increasing upstream blood pressure. Subsequent to implanting the flow diverting apparatus, the medication dosage may be increased above, or decreased below, the baseline dosage. The dosage may be increased if the medication is a beta-blocker, an angiotensin-receptor blocker, an angiotensin receptor enzyme inhibitor, a chymase inhibitor, a combination of an angiotensin receptor enzyme inhibitor and an angiotensin-receptor blocker, or a combination of an angiotensin receptor blocker and a neprilysin-inhibitor. The dosage may be decreased if the medication is a diuretic.